CPG1: A Potential Drug Target for Cancer Treatment (G9236)
CPG1: A Potential Drug Target for Cancer Treatment
Cell cycle progression 1, transcript variant 1 (CCPG1) is a gene that encodes for a protein known as p21. P21 is a key regulator of the cell cycle and is involved in the transition from the G1 phase to the S phase of the cell cycle. Mutations in the CCPG1 gene have been linked to various diseases, including cancer. As a result, CCPG1 has emerged as a promising drug target for the development of new treatments for these diseases.
The CCPG1 gene is located on chromosome 16 and encodes for a protein with 21 amino acid residues. The protein produced by the CCPG1 gene is a 21 kDa protein that is involved in the regulation of cell cycle progression. Specifically, it plays a role in the transition from the G1 phase to the S phase of the cell cycle.
During the G1 phase, the cell prepares for cell division by producing a series of proteins that are necessary for cell growth and division. These proteins include G1-specific proteins, such as cyclin D1, cyclin D2, and p20, as well as S-specific proteins, such as p21. P21 is a key regulator of the S phase and is involved in the transition from the G1 phase to the S phase.
Mutations in the CCPG1 gene have been linked to various diseases, including cancer. For example, studies have shown that mutations in the CCPG1 gene are associated with an increased risk of colorectal cancer. Additionally, studies have also shown that mutations in the CCPG1 gene are associated with an increased risk of breast cancer.
In addition to its role in cell cycle progression, P21 has also been shown to play a role in the regulation of cell growth and survival. For example, studies have shown that P21 can inhibit the activity of the oncogene transforming growth factor (TGF-2), which is involved in cell growth and survival.
As a result of its involvement in cell cycle progression and its potential role in the regulation of cell growth and survival, CCPG1 has emerged as a promising drug target for the development of new treatments for various diseases. For example, studies have shown that inhibiting the activity of P21 has the potential to treat various diseases, including cancer.
In conclusion, CCPG1 is a gene that encodes for a protein involved in the regulation of cell cycle progression. Mutations in the CCPG1 gene have been linked to various diseases, including cancer. As a result, CCPG1 has emerged as a promising drug target for the development of new treatments for these diseases. Further research is needed to fully understand the role of CCPG1 in cell cycle progression and its potential as a drug target.
Protein Name: Cell Cycle Progression 1
Functions: Acts as an assembly platform for Rho protein signaling complexes. Limits guanine nucleotide exchange activity of MCF2L toward RHOA, which results in an inhibition of both its transcriptional activation ability and its transforming activity. Does not inhibit activity of MCF2L toward CDC42, or activity of MCF2 toward either RHOA or CDC42 (By similarity). May be involved in cell cycle regulation
More Common Targets
CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48
